Myostatin is a negative regulator of muscle mass whose inhibition has been proposed as a therapeutic strategy for muscle-wasting conditions. Indeed, blocking myostatin action through different strategies has proved beneficial for the pathophysiology of the dystrophin-deficient mdx mouse. In this report, we tested the inhibition of myostatin by AAV-mediated expression of a mutated propeptide in animal models of two limb-girdle muscular dystrophies:
Introduction
Myostatin (growth differentiation factor-8) is a secreted growth factor belonging to the transforming growth factor-b (TGF-b) superfamily that acts as a negative regulator of skeletal muscle mass. A number of natural, inactivating mutations have been identified in cattle, mouse, sheep and human, all leading to a hypermuscular phenotype. [1] [2] [3] [4] [5] [6] The biological relevance of myostatin was also addressed in mice by gene inactivation, overexpression of normal or dominant-negative forms and systemic administration of inactivating antibody or myostatin protein. [7] [8] [9] [10] [11] [12] [13] [14] [15] From these studies and many others carried out in cultured cells, the general opinion is that myostatin regulates the final number of muscle fibers during development by blocking the proliferation and differentiation of myoblasts and also regulates the postnatal muscle-fiber size by maintaining the satellite cells in a quiescent state and inhibiting protein synthesis. 16, 17 Myostatin is synthesized as a 375-amino acids precursor composed of a signal sequence at the N-terminus, a 28 kDa propeptide region and a 12 kDa 'mature' region at the C-terminus. 16, 17 After proteolytic processing of this precursor, myostatin is secreted as an inactive latent complex of a disulfide-bond carboxy terminal dimer bound to the propeptide or other myostatin-binding proteins. 18 It has been suggested that one mechanism for activating myostatin consists of the proteolytic cleavage of the propeptide at the residue D76 by members of the bone morphogenetic protein-1/tolloid (BMP-1/TLD) family of metalloproteinases. 19 Following activation, the mature region binds to activin transmembrane receptors, which in turn initiate an intracellular signaling cascade, involving Smad proteins and leading to targeted gene transcription. 20, 21 Considering its effect on muscle growth, inhibition of myostatin has been proposed as a therapeutic approach in muscle-degenerative and wasting conditions, such as muscular dystrophies and cachexia. [22] [23] [24] [25] Indeed, improvement of the pathological signs of the dystrophin-deficient mdx mice model was obtained after crossing with myostatin null mice or after systemic injection of neutralizing monoclonal antibodies or a stabilized propeptide. [26] [27] [28] However, doubts have been raised whether myostatin inhibition leads to a truly healthy muscle as exercise in myostatin-deficient cattle led to early exhaustion. 29 Furthermore, it can even be deleterious as disused muscle atrophy is markedly more severe in the context of myostatin deficiency 30 and as crossing laminin-deficient dy(W) mice model with myostatin null mice led to an increased mortality. 31 These observations suggest that each individual situation has to be tested to define if they could benefit from myostatin blockade.
In this report, we investigated the effect of myostatin inhibition using a propeptide mutated at residue D76 on the pathophysiology of two animal models of recessive limb-girdle muscular dystrophies, LGMD2A (OMIM 253600) and LGMD2D (OMIM 608099).
LGMD2A is due to mutations in the muscle-specific cysteine protease calpain 3, the function of which is not fully deciphered but seems important for the correct homeostasis of the sarcomere. 32 LGMD2D is due to mutations in a-sarcoglycan, a transmembrane-protein part of the complex associated with dystrophin. [33] [34] [35] Adeno-associated virus (AAV)-mediated expression of the mutated form of the myostatin propeptide in the muscles of these two models led to different outcomes. In the highly regenerative Sgca-null mice, survival of the a-sarcoglycan-deficient muscle fibers did not improve after transfer of the myostatin propeptide. In calpain 3-deficient mice, a boost in muscle mass and an increase in absolute force were obtained, suggesting that myostatin inhibition could constitute a therapeutic strategy in this predominantly atrophic disorder.
Results

Effect of a mutated propeptide on muscle growth of normal mice
To obtain a myostatin propeptide that would have a more potent inhibitory effect on myostatin, we mutated the propeptide at the BMP-1/TLD cleavage site by replacing the aspartate at position 76 by an alanine residue (D76A). In addition, we replaced the signal sequence of the propeptide by the coding sequence of the murine-secreted alkaline phosphatase (mSeAP) to monitor the expression and secretion of the transgene. This construct was inserted into a rAAV2/1 vector under control of the cytomegalovirus (CMV) promoter to obtain the rAAV2/1-mSeAP-propmyoD76A vector (Figure 1) . A vector devoid of the propeptide (AAV2/1-mSeAP) was used as a control (Figure 1) . Two-month-old 129SV male mice were injected in the left tibialis anterior (TA) muscles either by rAAV2/1-mSeAP-propmyoD76A or the control rAAV2/1-mSeAP vectors. To verify that the presence of the propeptide at the C-terminus of mSeAP did not impair the phosphatase activity or prevent the secretion of the fused protein, we quantified mSeAP in blood from the injected animals and carried out phosphatase staining on muscle slices at the end point of the experiment. Six weeks after injection, a high number of positive fibers were observed throughout the muscle with both vectors (Figure 2a ). This efficient transduction was associated with significant amounts of mSeAP in blood samples, indicating that the fusion is permissive for the secretion of mSeAP (Figure 2a ). However, we noticed a higher intensity in fiber staining but a weaker blood level of mSeAP with rAAV2/1-mSeAP-propmyoD76A compared with rAAV2/1-mSeAP, suggesting that the secretion is not as efficient as in the former case.
To assess the effect of the expression of this construct on muscle growth, muscles were weighted at the end point of the experiment. Those injected with the rAAV2/ 1-mSeAP-propmyoD76A showed a mean increase of Figure 1 Diagram representing the AAV virus genomes used in this study. Figure 2b ). These results indicated that the fused propeptide was efficient in inducing growth in the injected muscle. In addition, it should be noted that the contralateral muscle of mice injected with rAAV2/ 1-mSeAP-propmyoD76A showed a significant increase of 15% compared with rAAV2/1-mSeAP-injected muscles (54.7574.37; P ¼ 0.01; Figure 2b ), indicating that the mutated propeptide had a weaker but real endocrine effect.
To determine whether this increase was due to hypertrophy or hyperplasia, we measured the number of fibers and the single fiber area (SFA). No significant change in the number of fibers between both groups was observed (rAAV2/1-mSeAP-injected TA: 33637454 and rAAV2/1-mSeAP-propmyoD76A-injected TA: 30557 182; P ¼ 0.336). However, we observed a 78% augmentation (P ¼ 0.002) of the SFA from 12367108 mm 2 for rAAV2/1-mSeAP to 21967192 mm 2 for rAAV2/ 1-mSeAP-propmyoD76A ( Figure 2c ). Detailed morphometric analyses of mSeAP negative fibers adjacent to positive fibers showed that these fibers had also undergone an increase in size, indicating that there is a paracrine effect of the propeptide ( Figure 2c ). As observed for the weight, a small increase was detected for the contralateral muscle (15867167 mm 2 ; P ¼ 0.038 versus mSeAP-injected muscles).
Injection of the mutated propeptide in two animal models of limb-girdle muscular dystrophies
Having demonstrated the ability of mSeAP-propmyo-D76A to induce muscle growth, we assessed its beneficial effect on pathology in a-sarcoglycan and calpain 3-deficient mice. Considering the benefit brought by myostatin inhibition in the mdx mice and the participation of a-sarcoglycan in the dystrophin-associated complex, we postulated that myostatin inhibition could be equally beneficial in the Sgca-null model. In addition, we speculated that myostatin inhibition could reverse the atrophic phenotype of the calpain 3-deficient mice.
We injected rAAV2/1-mSeAP-propmyoD76A or rAAV2/1-mSeAP into the left TA muscle of male mice of these models. To verify that the mSeAP-propmyo-D76A was also correctly expressed and secreted after intramuscular injection, we measured the amount of mSeAP in blood and sampled the muscles of the anterior compartment of the limbs at the end of the experiment (6 weeks after the injection). Unexpectedly, the level of mSeAP activity in the blood of Sgca-null mice hardly rose above the background level after injection of rAAV2/ 1-mSeAP-propmyoD76A (10 ng/ml; Figure 3a) . This low level of mSeAP was correlated with an expression in very few fibers as seen in a cross section of a representative left muscle (Figure 3b ). In contrast, an mSeAP secretion of intensity comparable to that observed in the data obtained with wild-type (WT) mice was observed in calpain 3-deficient mice (Figure 3a ; 263 ng ml À1 for the calpain 3-deficient mice compared with 176 ng ml À1 for control mice; P ¼ 0.1). This secretion was associated with a large number of fibers expressing the transgene on muscle cross sections ( Figure 3b) .
As expected from the absence of mSeAP expression, the injected muscles of Sgca-null mice did not increase in mass (Figure 3c ), nor were they improved in their susceptibility to necrosis as monitored by Blue Evans staining (data not shown). Considering the absence of hypertrophic benefit in the highly regenerative Sgca-null mice, we did not further analyze these mice. In contrast, the high level of expression obtained with the calpain 3-deficient mice was associated with an increase of 31% in the mass of the injected muscles compared with the mSeAP-injected muscles (59.0374.8 versus 44.8774.43; P ¼ 0.04; Figure 3c ).
Effect on the pathology in the calpain 3-deficient mice
The morphological analyses carried out on calpain 3-deficient mice limbs showed that the total number of fibers was not significantly different after treatment AAV-mediated delivery of a mutated myostatin propeptide M Bartoli et al (32107401 versus 35577312; P ¼ 0.529). However, the SFA increased about 54% (18387157 versus 11957 151 mm 2 for mSeAP; P ¼ 0.007), indicating that the hypertrophic phenotype was mainly because of an increase in fibers size as observed in WT animals (Figure 4a) . No drastic improvement of the histology of the treated muscles was noticed ( Figure 4b ). As calpain 3 deficiency has been proposed to alter the maturation of the muscle fibers by delaying sarcomere formation, 36 we labeled control and treated muscles with a developmental form of myosin heavy chain (MHCd). No difference was detected between injected and non-injected muscles (Figure 4c ). Specifically, we did not detect any accumulation of MHCd-positive fibers over time in calpain 3-deficient muscles.
To test if mSeAP-propmyoD76A-induced hypertrophy could strengthen calpain 3-deficient muscles, we performed a femoral intra-arterial injection of the rAAV2/ 1-mSeAP-propmyoD76A in 5-month-old males. An increase in the mass of muscles was observed after injection of rAAV2/1-mSeAP-propmyoD76A (TA 47.3%, P ¼ 0.002; gastrocnenius 38%, P ¼ 0.011; quadriceps 24%, P ¼ 0.01 and extensorum digitorum longus (EDL) 48.3%; P ¼ 0.001). However, this increase did not reflect on the body weight (P ¼ 0.26). EDL and soleus muscles were then processed for in vitro analysis of contractile force as described previously. 37 The maximum absolute isometric tetanic force was 341756 mN in EDL from rAAV2/1-mSeAPpropmyoD76A-injected limbs versus 208732 mN (Po0.001) from mSeAP-injected limbs (Table 1 and Figure 4c ). The maximum absolute isometric tetanic force was 114745 mN in soleus from rAAV2/1-mSeAPpropmyoD76A-injected limbs versus 61712 mN (P ¼ 0.005) from mSeAP-injected limbs (Table 1 and Figure  4d ). However, when the force was normalized for the muscle cross-sectional area (specific isometric tetanic force), the difference fell below the limit of significance (Table 1) . It can also be noted from these analyses that T 50 (half relaxation time of tetanus), an indicator reflecting the composition of fiber, was not modified (Table 1) .
Discussion
We treated Sgca-null and calpain 3-deficient mice with a recombinant AAV encoding a mutated propeptide to determine whether myostatin inhibition could alleviate the pathological signs in these models. We observed different outcomes depending on the deficiencies with a boost of the muscle mass associated with an increase of the force of the muscle obtained only in calpain 3-deficient mice.
The propeptide used in this study was mutated at the proteolytic cleavage site between R75 and D76. A cleavage in this region was shown to induce propeptide release from myostatin, hence resulting in activation of the latent complex. 19 Indeed, cleavage of the propeptide by BMP-1/TLD at this location was proposed to be an activation mechanism of myostatin, 19 but this has yet to be demonstrated in vivo. It is interesting to note that one study reported that injection of Fc-fused propeptide is effective in inducing hypertrophy in WT female mice only when mutated at the corresponding residue. 19 In our experiments, rAAV-mediated injection of the mutated propeptide induced hypertrophy to an extent overrating both what we obtained with a WT propeptide (a 20-30% increase; data not shown) and what was reported in the literature in normal adult mice. 12 These elements suggest that the presence of the mutation could indeed be considered an advantage. However, additional AAV-mediated delivery of a mutated myostatin propeptide M Bartoli et al experiments would be needed to fully comprehend whether the mutation would make any difference depending on the mode of propeptide delivery, the duration of its presence in the organism and/or the physiological or pathological condition of the muscle. Using injection of rAAV2/1-propmyoD76A for blockade of myostatin is inefficient in the Sgca-null mice. The level of expression obtained with this vector is equivalent to the expression of a reporter transgene, such as mSeAP and much lower than a therapeutic one injected at the same age. 38 As an explanation, it can be suggested that any propeptide that may be expressed in fibers did not circumvent the membrane-related degenerative process. This hypothesis is consistent with the absence of reversal of stretch sensitivity observed in the mdx mice after pharmacological blockade of myostatin, 26, 28 suggesting that membrane destabilization persists even if the muscle is stronger. Alternatively, considering that we used a ubiquitous promoter to drive the expression of mSeAP, it is possible that an immune response was elicited in the highly inflammatory muscle tissue of the Sgca-null mice. Whatever the hypotheses, a clearance of the vector from the tissue is ultimately achieved. Nonetheless, whereas the present strategy was proved to be inefficient, it remains to be seen if other approaches using expression from another organ or with a different mode of action, such as the use of neutralizing antibody could be beneficial for a-sarcoglycan deficiency, as it has been shown in mdx mice. 26, 28 In contrast to the situation with the Sgca-null mice, inhibition of myostatin in the calpain 3-deficient model not only induced muscle growth but also increased the absolute tetanic force of the muscle. The positive effect obtained in this case compared with what was observed in the Sgca-null mice can be put in relation to the difference in turnover of fibers in those two deficiencies, reflecting a distinction in the pathophysiological mechanisms. For Sgca-null mice, the loss of a-sarcoglycan at the membrane leads to leakiness of the membrane, excess of calcium influx, aberrant activation of calcium-dependent proteases, unwanted proteolysis and finally cell death. For the calpain 3-deficient model, the pathophysiological mechanism is less clear, considering that the function of this protease is not fully understood. However, it seems that calpain 3 is necessary for remodeling of the cytoskeleton, leading, in case of deficiency, to abnormal sarcomeres associated with an increase in cellular stress. 31 In contrast with the human situation where these events seem to induce an increase in cell death by apoptosis, it is less clear that it occurs in mice, explaining the low rate of turnover.
The level of forces obtained after transfer even exceeds that achieved after AAV-mediated calpain 3 gene transfer. 39 Calpain 3 was proposed to participate in the maturation and growth of the muscle fibers, as its deficiency induced a delayed sarcomere formation and a decrease of the rate of mass recovery following hindlimb suspension. 36, 40 Considering this hypothesis and as increase in muscle mass and augmentation of force of the individual myofibers necessitates new incorporation of sarcomeres, it was not a priori evident that myostatin inhibition would be efficient in the absence of calpain 3. In fact, we observed that the level of growth of individual myofibers was not significantly different between WT-and calpain 3-deficient muscles (analysis of variance (ANOVA): P ¼ 0.09) even if growth seems less efficient than in WT animals when the whole muscle is considered (ANOVA analysis: P ¼ 0.02). This discrepancy could be related to the dystrophic state of the muscle tissue, which includes a non-responsive fraction constituted by fibrosis and inflammatory infiltrates. In addition, results of the tension and T 50 indicated that muscle growth in the context of calpain 3 deficiency is not associated with a drastic modification of mechanistic quality of the sarcomere. This, together with the absence of accumulation of MHCd-positive fibers, seems to indicate that the increase of muscle mass induced by myostatin inhibition is not associated with deleterious myofibrillogenesis in the context of calpain 3 deficiency. Altogether, the positive effects on the atrophy and force shown herein are encouraging for the use of myostatin inhibition to alleviate the LGMD2A symptoms, widening the possible application of this strategy.
Materials and methods
Vector construction and production
To construct the pAAV-CMV-mSeAPpropmyoD76A, the coding sequence of mSeAP (without the stop codon) was amplified from the pVT20 plasmid (a gift from Vincent Thuiller AAV-mediated delivery of a mutated myostatin propeptide M Bartoli et al
The propeptide sequence of myostatin with its sequence signal deleted was also subcloned by TOPO cloning to generate the pCR-PropMyo plasmid after amplification with oligonucleotides MusPro-KpnI-F 5 0 -GGGGTACCTGTAATGCATGTGCGTGGAGA-3 0 and MusPro-BamHI-R 5 0 -CGCGGATCCCCTATTAGTCTCTC CGGGACCTCTT-3 0 on a pAAV plasmid, where the propeptide was previously cloned from murine skeletal muscle cDNA. The mutation D76A was introduced in this plasmid using QuikChange Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA, USA) with the primers D76A.up: 5 0 -CAGTACGACGTCCAGAGGGCT GACAGCAGTGATGGCTCT-3 0 and D76A.bot: 5 0 -AGAG CCATCACTGCTGTCAGCCCTCTGGACGTCGTACTG-3 0 . The plasmid pAAV-CMV-mSeAPropmyo was then constructed by successively subcloning a XhoI-KpnI fragment containing the mSeAP coding sequence from pCR-SeAP and a KpnI-KpnI fragment containing the myostatin propeptide from pCR-Propmyo into an AAV-based pSMD2-derived vector. 42 The plasmids pAAV-mSeAP and pAAV-CAPN3 were previously described. 39, 43 Plasmid DNA was prepared using the EndoFree Megaprep kit (Hoerdt, France) from Macherey-Nagel. All constructs were subjected to automated sequencing to verify integrity of the constructs. Adenovirus-free AAV2/1 viral preparations were generated by packaging AAV2-ITR recombinant genomes in AAV1 capsids using a three plasmid transfection protocol. 44 Physical particles were quantified by a quantitative TaqMan assay. 45 
Animal experiments
A murine knockout for a-sarcoglycan was obtained from K Campbell (Howard Hughes Medical Institute, Iowa City, IA, USA). The construction and characterization of this model was previously described. 46 The construction and characterization of calpain 3-deficient model was previously described. 37, 47 Control male mice from the 129SV strains were purchased from Charles River Laboratories (Les Oncins, France). All mice were handled according to the European guidelines for the humane care and use of experimental animals.
For intramuscular injection, 129SV or deficient mice were injected with 25 ml (6 to 1.3 Â 10 10 viral genomes (vg) per injection) of rAAV viral preparation at the age of 2 months for WT and calpain 3-deficient mice and at the age of 5 weeks to 2 months for Sgca-null mice. Detailed procedure for intra-arterial injection was previously described. 48 Briefly, anesthetized mice underwent femoral artery and vein isolation of the right hindlimb. After clamping the femoral vein and two collaterals, a catheter was introduced in the femoral artery and the rAAV preparation (2.5 Â 10 12 vg per injection) was injected in a volume of 1 ml 20 À1 g of body weight at a rate of 100 ml s
À1
. Blood samples were obtained every week by retroorbital puncture of anesthetized animals. Detection of mSeAP in those samples was carried out as described previously. 39 The EDL and SOL muscles were surgically excised for measurement of isometric contractile properties in vitro, maintained in Krebs buffer and processed as described previously. 37 The following parameters were studied: P 0 , the maximum tetanic force and T 50 , the duration to a P 0 decrease by 50%. Isometric tension was calculated by dividing the force by estimated cross-sectional area of the muscle.
Immunofluorescence, histological and morphometric analyses
Cryosections (8 mm thickness) were prepared from frozen muscles. Transverse sections were processed for hematoxylin and eosin (H&E) histological staining. Detection of mSeAP on muscle slices were carried out as described previously. 39 For immunohistochemical detection of MHCdpositive fibers, cryosections were blocked with phosphate buffered saline (PBS)+10% goat serum for 1 h and then incubated in a humid chamber with a 1/40 dilution of primary antibody (NCL-MHCd, Novocastra, Antony, France) for 1 h at room temperature (RT). After washing with PBS 1 Â , sections were incubated with a goat antimouse secondary antibody conjugated with Alexa488 (Molecular Probes, Paisley, UK) dye-diluted 1/1000 (A-11070, Molecular Probes) for 1 h at RT. Sections were mounted with Fluoromount-G (Cliniscience, Montrouge, France) after 4,6-diamidino-2-phenylindole (DAPI) staining and visualized on a Leica confocal fluorescence microscope. For immunohistochemical staining of slowtype fibers, an antibody against the skeletal slow myosin (M8421, Sigma, Lyon, France) was used and the detection was carried out according to the ARK peroxidase kit (Dako, Trappes, France).
For morphological analysis, unfixed transverse cryosections were treated for 20 min with H 2 O 2 to inhibit endogenous peroxidase, blocked with PBS+10% goat serum for 30 min and then incubated with 1/400 dilution of polyclonal rabbit anti-laminin primary antibody (10765, Progen) for 2 h at RT. After washing with PBS, sections were incubated with a goat anti-rabbit HRPlabeled antibody (1:200 dilution, P 0448, Dako) for 1 h at RT. Sections were mounted with Eukitt (Labonord, Villeneuve, D'ASCQ, France) after treatment with diamino-3,3 0 benzidine. Digital images were captured using a CCD camera (Sony) and processed using Ellix software (Microvision, Evry, France).
Statistical analysis
Data for each group are represented as the mean plus standard deviation (s.d.). Differences between classes were determined using the Student's paired t-test. Differences between the percentages of increase in muscle mass or in SFA between WT and calpain 3-deficient mice were assessed using one-way ANOVA. All statistical tests were considered to be significant when the error was below 5%.
